Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026
Breast cancer tumor immune microenvironment landscape identifies prognostic risk genes and potential drugs.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Baoquan, Bao Daode, Zhao Lianyou, Liu Yuyu, Gao Ziyu, Zeng Yue, Zhou Guiqin, Zong Yonghua, Mao Chunmei, Lv Fuchun, Sheng Jiahui, Shi Hongji, Su Fei
Аннотация
Breast cancer (BRCA) is the most common type of cancer among women. The tumor immune microenvironment (TIM) influences the early progression of BRCA and is related to its clinical characteristics and outcomes. But the underlying mechanisms remain unclear. In this study, four synergistic TIM-prognosis-related genes (CD1C, CD40LG, CXCR3, CD69) were obtained which were significantly associated with tumor purity, and higher TIM-related immune activity was associated with improved prognosis in BRCA patients. A microRNA-mRNA-transcription factor regulatory network was established, revealing upstream regulators of these genes. Furthermore, fourteen candidate drugs targeting this network were predicted, and structural analogs of Lumacaftor and Ivosidenib showed promising docking affinities to CD1C and CXCR3, respectively. These findings provide preliminary insights into TIM-associated prognostic pathways and suggest candidate compounds for further investigation in BRCA.